Small cell lung cancer extensive stage
Information
- Disease name
- Small cell lung cancer extensive stage
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04670445 | Active, not recruiting | N/A | Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer | January 23, 2021 | April 2024 |
| NCT03923270 | Active, not recruiting | Phase 1 | Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer | June 6, 2019 | June 1, 2024 |
| NCT04462276 | Active, not recruiting | Phase 2 | Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease | July 28, 2020 | August 2024 |
| NCT03059667 | Completed | Phase 2 | Immunotherapy as Second-line in Patient With Small Cell Lung Cancer | March 13, 2017 | December 1, 2020 |
| NCT03325816 | Completed | Phase 1/Phase 2 | Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer | November 20, 2017 | August 11, 2020 |
| NCT05066945 | Not yet recruiting | Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients | January 1, 2022 | December 31, 2026 | |
| NCT06429696 | Not yet recruiting | Phase 2 | PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer | May 14, 2024 | April 30, 2026 |
| NCT06348797 | Not yet recruiting | Phase 1 | Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC | June 1, 2024 | December 31, 2026 |
| NCT05745350 | Not yet recruiting | Phase 2 | First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC | November 2023 | December 2025 |
| NCT05680922 | Recruiting | Phase 1 | DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer | July 26, 2023 | March 2028 |
| NCT06187740 | Recruiting | Phase 1 | Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy | December 1, 2023 | December 31, 2025 |
| NCT06030258 | Recruiting | Phase 1/Phase 2 | IN10018 Combination Therapy in Treatment-naïve ES-SCLC | October 30, 2023 | October 21, 2025 |
| NCT05945745 | Recruiting | Molecular Analysis and Treatment Options of SCLC | January 1, 2016 | December 31, 2028 | |
| NCT05856695 | Recruiting | Phase 2 | A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC) | November 17, 2023 | February 2028 |
| NCT05384015 | Recruiting | Phase 2 | Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer | November 7, 2022 | July 30, 2027 |
| NCT05703971 | Recruiting | Phase 1/Phase 2 | Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients | May 9, 2024 | August 2027 |
| NCT05027867 | Terminated | Phase 2 | KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | December 6, 2021 | August 26, 2022 |
| NCT00003496 | Terminated | Phase 2 | Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer | March 7, 1996 | February 5, 2004 |
| NCT04967625 | Unknown status | Phase 2 | A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC | July 26, 2021 | December 31, 2023 |
| NCT04659785 | Unknown status | Phase 1/Phase 2 | A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC） | July 1, 2020 | December 31, 2022 |
| NCT03994744 | Unknown status | Phase 2 | Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC | August 20, 2019 | July 1, 2022 |
| NCT03755115 | Unknown status | Phase 2 | SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer | February 1, 2019 | May 31, 2020 |
| NCT03253068 | Unknown status | Phase 2 | Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer | August 1, 2017 | December 31, 2020 |
| NCT02179528 | Unknown status | Phase 2 | Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC) | September 2014 | September 2017 |